by Richard Daverman, PhD
March 11, 2013 -- Simcere Pharma, a Nanjing maker of branded generics and proprietary drugs, has joined the stampede of China pharmaceutical companies that may go private. The company, which posted 2012 revenues of $334 million last week, received an offer of $9.56 per ADS from its chairman and several related entities. The offer values Simcere at $503 million and represents a premium of 19% from the close on Friday. Simcere has formed a number of very interesting partnerships, whose payoffs, if they occur, remain in the future. More details....
Stock Symbol: (NYSE: SCR)
